Do tofacitinib generics exhibit conventional synthetic disease-modifying anti-rheumatic drug and non-steroidal anti-inflammatory drug-sparing ability in the management of axial spondyloarthritis
JavaScript is disabled for your browser. Some features of this site may not work without it.
Do tofacitinib generics exhibit conventional synthetic disease-modifying anti-rheumatic drug and non-steroidal anti-inflammatory drug-sparing ability in the management of axial spondyloarthritis